

William (Bill) Rastetter

Partner with Venrock; Former Executive Chairman, Biogen Idec



In addition to his role at Venrock, Dr. Rastetter serves as Chairman and CEO of Apoptos, a San Diego based development-stage company focused on the development of targeted, small molecule cancer therapies. He today also serves as the Chairman of Illumina, Inc. (NASDAQ). Bill was previously Executive Chairman of Biogen Idec, from the merger of the two companies in 2003 through the end of 2005. Bill joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as Chairman and CEO. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served as well in a scientific capacity at Genentech. Adding to his corporate background, Bill

held various faculty positions at MIT, won the award for “Excellence in the Teaching of Chemistry” at Harvard and is an Alfred P. Sloan Fellow. Bill is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology. Bill earned his PhD and MA in Chemistry from Harvard University.